March 2026 in “Photodermatology Photoimmunology & Photomedicine” Patients with skin immune diseases need better education on UV protection to improve compliance.
1 citations
,
December 2024 in “Case Reports in Dermatology” Cyclophosphamide likely causes skin darkening by affecting hair follicles.
Diseased horse foot skin shows increased keratin expression, similar to wound healing in mammals.
11 citations
,
February 2019 in “Research and reports in forensic medical science” DNA phenotyping helps predict physical traits from DNA with varying accuracy and requires careful ethical and legal handling.
29 citations
,
February 1989 in “Journal of Cutaneous Pathology” A unique hair tumor with a rippled pattern was identified, showing incomplete differentiation and unusual cell arrangements.
April 2019 in “Institutional Repositories DataBase (IRDB)” Patient-derived stem cell melanocytes could be a promising treatment for vitiligo.
17 citations
,
November 2017 in “PLoS ONE” Transplanted bone marrow cells actively move, form clusters, and grow after transplantation.
7 citations
,
October 2008 in “Arthritis Care & Research” Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.
April 2023 in “Journal of Investigative Dermatology” IL-17 plays a key role in severe hair loss in chronic alopecia areata.
2 citations
,
September 2014 in “Nature reviews. Drug discover/Nature reviews. Drug discovery” Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.
106 citations
,
December 2015 in “Journal of The American Academy of Dermatology” Correct skin biopsy techniques are crucial to avoid misdiagnosis of skin diseases.
November 2024 in “Journal of Investigative Dermatology” Certain NK cell changes in blood may indicate alopecia areata progression.
May 2025 in “The Journal of Rheumatology” Purpura fulminans can signal underlying autoimmune disorders, not just infections.
5 citations
,
October 2015 in “The American journal of pathology” Mice with a mutated Dsg3 gene showed severe symptoms but not the typical blistering of pemphigus vulgaris.
October 2025 in “Communications Medicine” Combining genetic and physical data improves diagnosis and treatment for early-onset monogenic diabetes.
32 citations
,
July 2003 in “Histochemistry and Cell Biology” January 2018 in “Journal of Investigative Dermatology” Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
66 citations
,
December 2014 in “Nature Communications” Fibroblasts can be turned into melanocytes for potential skin treatments.
4 citations
,
January 2012 in “Chemical Immunology” Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.
15 citations
,
September 2014 in “PloS one” The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.
4 citations
,
March 2024 in “Forensic Sciences Research” Forensic DNA phenotyping faces challenges like inconsistent terms and limited genetic knowledge.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
May 2018 in “The journal of immunology/The Journal of immunology” Mutations in the FOXN1 gene cause severe immune issues but don't affect hair and nails.
28 citations
,
December 2005 in “Oncogene”
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
1 citations
,
July 2025 in “Frontiers in Genetics” FilaggrinHigh melanomas have active FGFR signaling and weak GNA14 and Th1 signatures.
July 2024 in “Journal of Investigative Dermatology” Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.